Engineering safe anti-CD19-CD28ζ CAR T cells with CD8a hinge domain in serum-free media for adoptive immunotherapy
BackgroundDespite the curative potential, high cost of manufacturing and the toxicities limits the wider access of Chimeric Antigen Receptor (CAR) T cell therapy in global medicine. CARs are modular synthetic antigen receptors integrating the single-chain variable fragment (scFv) of an immunoglobuli...
Saved in:
| Main Authors: | Muthuganesh Muthuvel, Thamizhselvi Ganapathy, Trent Spencer, Sunil S. Raikar, Saravanabhavan Thangavel, Alok Srivastava, Sunil Martin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1545549/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CD4+/CD8- T cell large granular lymphocytic leukemia: A rare entity
by: Ashish Gupta, et al.
Published: (2019-01-01) -
Advances in CAR optimization strategies based on CD28
by: Sijin Li, et al.
Published: (2025-03-01) -
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity
by: Sara Caratelli, et al.
Published: (2025-02-01) -
Co-stimulation of CD28/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness
by: Wannakorn Khopanlert, et al.
Published: (2024-09-01) -
MiR-214 regulates CD3ζ expression in T cells
by: Yankai Xiao, et al.
Published: (2019-07-01)